login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
INNOVIVA INC (INVA) Stock News
USA
- NASDAQ:INVA -
US45781M1018
-
Common Stock
17.71
USD
-0.55 (-3.01%)
Last: 10/24/2025, 8:00:02 PM
17.71
USD
0 (0%)
After Hours:
10/24/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
INVA Latest News, Press Relases and Analysis
All
Press Releases
5 days ago - By: Antheia
Antheia Appoints Eric d'Esparbes as Chief Financial Officer
6 days ago - By: Innoviva Specialty Therapeutics
Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025
19 days ago - By: Innoviva Specialty Therapeutics
Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025
26 days ago - By: Benzinga
Beyond The Numbers: 5 Analysts Discuss Innoviva Stock
3 months ago - By: Benzinga
Expert Outlook: Innoviva Through The Eyes Of 4 Analysts
3 months ago - By: The Motley Fool
Innoviva (INVA) Q2 Sales Jump 64%
2 months ago - By: Innoviva, Inc.
Innoviva to Participate in Upcoming Investor Conferences
2 months ago - By: Innoviva Specialty Therapeutics, Inc.
Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award
3 months ago - By: Yahoo Finance
- Mentions:
MS
CMI
HSBC
LINE
...
Arm initiated, Adobe downgraded: Wall Street's top analyst calls
3 months ago - By: Innoviva, Inc.
Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress
5 months ago - By: Innoviva Specialty Therapeutics, Inc.
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025
5 months ago - By: Innoviva, Inc.
Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults
5 months ago - By: Innoviva, Inc.
Innoviva to Participate in Upcoming Investor Conferences
5 months ago - By: Innoviva Specialty Therapeutics, Inc.
ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections
6 months ago - By: Yahoo Finance
- Mentions:
MSFT
AMZN
Innoviva, Inc. (INVA): Among Stocks with Insanely High PE Ratios Insiders Are Selling
6 months ago - By: Innoviva, Inc.
Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress
8 months ago - By: Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva
8 months ago - By: Innoviva, Inc.
Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference
8 months ago - By: Innoviva, Inc.
Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress
9 months ago - By: Innoviva, Inc.
Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
10 months ago - By: Innoviva, Inc.
Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)
a year ago - By: Innoviva, Inc.
Innoviva to Participate in the Citi 2024 Global Healthcare Conference
a year ago - By: Innoviva, Inc.
Innoviva to Participate in the UBS Global Healthcare Conference
Please enable JavaScript to continue using this application.